January 2, 2026

Abivax SA (ABVX) Stock Analysis: A Biotech Powerhouse with 7.75% Potential Upside

Investors with a keen eye for the biotechnology sector may want to turn their attention to Abivax SA (ABVX), a French clinical-stage biotech firm that is making waves with its..

Kamada Ltd. (KMDA) Stock Analysis: Unearthing an 84% Upside Potential in the Healthcare Sector

Kamada Ltd. (NASDAQ: KMDA), an Israeli healthcare company specializing in plasma-derived protein therapeutics, is currently making waves in the drug manufacturing industry with a striking potential upside of 84.14%. For..

AngioDynamics, Inc. (ANGO) Stock Analysis: Exploring a 50% Upside Potential with Analyst Confidence

AngioDynamics, Inc. (NASDAQ: ANGO), a prominent player in the healthcare sector, is catching the attention of investors, particularly due to its impressive potential upside. With a market capitalization of $529.01..

Autolus Therapeutics plc (AUTL): Analyst Optimism with a 384% Potential Upside

Autolus Therapeutics plc (NASDAQ: AUTL), a UK-based biotechnology firm, is gaining attention from investors with a significant potential upside of 384.09%. Specializing in the development of T cell therapies targeting..

COMPASS Pathways (CMPS): Potential 143% Upside as Psilocybin Therapy Nears Key Milestones

COMPASS Pathways Plc – American (CMPS), a trailblazer in the mental health sector, has captured the attention of investors with a compelling upside potential of 143.74%. This UK-based biotechnology firm,..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring a 155.71% Potential Upside in the Biotech Sector

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) presents an intriguing opportunity within the biotechnology sector, boasting a market capitalization of $796.64 million. As a clinical-stage biopharmaceutical company, Oric is focused on developing..

MeiraGTx Holdings plc (MGTX)

⚠️ No article content returned.

..

Emergent BioSolutions Inc. (EBS) Stock Analysis: Uncovering a 9.22% Potential Upside Amidst Strategic Healthcare Endeavors

Emergent BioSolutions Inc. (NYSE: EBS), a key player in the healthcare sector, specializes in providing critical preparedness and response solutions for various public health threats. With a market cap of..

Arvinas, Inc. (ARVN) Stock Analysis: Navigating the Biotechnology Frontier with PROTAC Innovation

Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage biotechnology company, stands at the forefront of pioneering therapies that leverage the body’s natural mechanisms to target and degrade disease-causing proteins. With a market..

Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 718% Upside in Biotechnology

Investors with an appetite for high-risk, high-reward opportunities might find Humacyte, Inc. (NASDAQ: HUMA) an intriguing candidate. Operating within the biotechnology sector, Humacyte stands out with its innovative approach to..

Prothena Corporation plc (PRTA) Stock Analysis: A Biotech Firm with 112.91% Potential Upside

Prothena Corporation plc (NASDAQ: PRTA) has been drawing considerable attention from investors in the biotechnology sector, thanks to its promising pipeline and a potential upside of 112.91% based on analyst..

Organogenesis Holdings Inc. (ORGO) Stock Analysis: Exploring 64% Potential Upside Amidst Strong Revenue Growth

Organogenesis Holdings Inc. (NASDAQ: ORGO), a leader in regenerative medicine, is making waves in the healthcare sector with its advanced wound care and surgical products. As the company continues its..

EyePoint, Inc. (EYPT) Stock Analysis: A Biotech Gem with Nearly 98% Upside Potential

Investors seeking high-growth opportunities in the biotechnology sector might find EyePoint, Inc. (NASDAQ: EYPT) particularly compelling. With a focus on developing groundbreaking therapeutics for retinal diseases, EyePoint is positioned at..

Inventiva S.A. (IVA) Stock Analysis: 229% Potential Upside Captivates Investors

Investors with a keen eye on the biotechnology sector should take note of Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company based in Daix, France. Specializing in innovative small molecule therapies,..

Cogent Biosciences, Inc. (COGT) Stock Analysis: Potential 38% Upside as Analysts Show Strong Buy Interest

Cogent Biosciences, Inc. (NASDAQ: COGT) is capturing the attention of investors with its significant potential upside and robust analyst support. As a biotechnology company focused on precision therapies for genetically..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a 25% Upside Potential in the Biotech Space

Tyra Biosciences, Inc. (NASDAQ: TYRA), a clinical-stage biotechnology company, is turning heads in the investment community with its promising advancements in precision medicine. With a market capitalization of $1.4 billion,..

Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a 72% Potential Upside Amid Strong Buy Ratings

Rapport Therapeutics, Inc. (NASDAQ: RAPP) is emerging as a noteworthy player in the biotechnology industry with its focus on innovative treatments for central nervous system disorders. As a clinical-stage biopharmaceutical..

Atai Beckley N.V (ATAI): Investor Outlook on a Biotech Powerhouse with 203% Potential Upside

Atai Beckley N.V. (NASDAQ: ATAI) is capturing attention across the investment landscape with its substantial 203% potential upside, as indicated by analyst target prices. As a clinical-stage biopharmaceutical company, Atai..

Auna SA (AUNA) Stock Analysis: Exploring a Potential 111.72% Upside in the Healthcare Sector

Auna SA (AUNA), a prominent player in the healthcare sector, operates a network of hospitals and clinics across Mexico, Peru, and Colombia. Based in Luxembourg, the company offers a range..

Maravai LifeSciences Holdings (MRVI) Investor Outlook: Navigating the Biotech Terrain with a 20.88% Upside Potential

Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) stands as a noteworthy player within the biotechnology industry. With a market capitalization of $1.19 billion, Maravai operates primarily in the healthcare sector, focusing..

Search

Funds

January 2, 2026

Search

Funds

January 2, 2026

FTSE 100

Funds